Monday's trading session has seen significant activity among stocks across different market capitalization ranges. Notably, Tesla (NASDAQ:TSLA), Xpeng Inc (NYSE:XPEV) and Summit Therapeutics PLC (NASDAQ:SMMT) have experienced notable intraday price movements. As the market progresses, these stocks, alongside others from the mega-cap and large-cap categories, are shaping the day's financial narrative. Here's a look at some of the key stock movers, from the largest companies to those with smaller market valuations.
Mega-Cap Movers
- Tesla (TSLA); sees continued momentum following better earnings/margins last week: 1.4% higher;
Large-Cap Stock Movers
- Summit Therapeutics PLC (SMMT); PESG Releases Market Update: +5.54%
- MicroStrategy Inc (MSTR); gains on strength in Bitcoin; +5.45%
- Ke Holdings Inc (BEKE); +5.65%
- Tencent (HK:0700) Music Entertainment Group (NYSE:TME); +4.57%
- Coinbase Global (NASDAQ:COIN); +4.16%
- Xpeng Inc (XPEV); +8.4%
- NIO Inc (NIO); +8.94%
- Affirm Holdings (NASDAQ:AFRM); +6.93%
- Carnival Corp-Exch (NYSE:CCL); +3.97%
- Albemarle (NYSE:ALB); +5.87%
Mid-Cap Stock Movers
- Procept Biorobotics (PRCT); PROCEPT BioRobotics Reports Third Quarter 2024 Financial Results: +30.01%
- AltC Acquisition (OKLO); +23.86%
- NantKwest (NASDAQ:IBRX); +21.05%
- Vera Therapeutics (VERA); +13.65%
- Miniso Group Holding Ltd (MNSO); +9.65%
- Ikonics Corp (WULF); +10.03%
- Yandex (NASDAQ:NBIS); +10.27%
- DJ Transportation Average (DJT); +1.01%
Small-Cap Stock Movers
- Monte Rosa Therapeutics (GLUE); Monte Rosa inks $150 million Novartis (LON:0QLR) (SIX:NOVN) deal for MRT-6160: +68.3%
- pSivida Corp (EYPT); EyePoint reports positive DURAVYU trial results for DME: +34.32%
- Revance The (RVNC); +26.06%
- Septerna Inc (SEPN); +18.89%
- Serve Robotics (SERV); +18.4%
- Nuscale Power (NYSE:SMR); +15.89%
- Prothena Corporation PLC (PRTA); +17.65%
- Stratasys (NASDAQ:SSYS); +14.35%
- nLIGHT Inc (NASDAQ:LASR); +17.33%
For real-time, market-moving news, join Investing Pro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.